alemtuzumab,venetoclax
abbvie,roche,sanofi
['venetoclax', 'lymsm', 'alemtuzumab']
t-pll incidence &amp; survival patterns - vardell
- incidence 0.49/1million (has incr maybe due to better diag)
- more common: male, black
- med os 1.4y with slight improvement in more recent times ?due to alemtuzumab
very poor outcomes - new therapies urgently needed.
#ash22 #lymsm 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.